Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07285557
Vupanorsen · 1 trial · 3 indications
Fasting was required at least 10 hours before blood sample collection. Baseline was calculated using the average of all values obtained at Screening and on Day 1 prior to dosing.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | No drug |
| Vupanorsen 80 mg every 4 weeks | EXPERIMENTAL | 80 milligrams (mg) given subcutaneously every 4 weeks. |
| Vupanorsen 60 mg every 2 weeks | EXPERIMENTAL | 60 mg given subcutaneously every 2 weeks. |
| Vupanorsen 120 mg every 4 weeks | EXPERIMENTAL | 120 mg given subcutaneously every 4 weeks. |
| Vupanorsen 80 mg every 2 weeks | EXPERIMENTAL | 80 mg given subcutaneously every 2 weeks. |
| Vupanorsen 160 mg every 4 weeks | EXPERIMENTAL | 160 mg given subcutaneously every 4 weeks. |
| Vupanorsen 120 mg every 2 weeks | EXPERIMENTAL | 120 mg given subcutaneously every 2 weeks. |
| Vupanorsen 160 mg every 2 weeks | EXPERIMENTAL | 160 mg given subcutaneously every 2 weeks. |
| Name | Type | Description |
|---|---|---|
| Vupanorsen | DRUG | Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used. |
| Placebo | DRUG | Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used. |
Inclusion Criteria: 1. Male or female participants aged ≥40 years at Screening. 2. Fasting non-HDL-C at Screening ≥100 mg/dL. 3. Fasting TG at Screening of 150 to 500 mg/dL, inclusive, which may be repeated once if deemed necessary. 4. Participants must be on a stable dose of a statin for at least ...
Vupanorsen is an investigational RNA therapy being studied for dyslipidemias, a group of conditions involving abnormal levels of lipids such as cholesterol and triglycerides in the blood. It is being developed by Pfizer and has been evaluated in a Phase 2 clinical trial in adults with dyslipidemias, hyperlipidemias, and hyperlipoproteinemias.
Vupanorsen targets ASGR1 and ANGPTL3. It is an RNA therapy designed as a binding agent directed at these molecular targets. ANGPTL3 is involved in regulating lipid metabolism, and ASGR1 is a receptor expressed on liver cells. By targeting these proteins, Vupanorsen aims to affect lipid levels in the blood.
Vupanorsen is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the company responsible for the clinical development of this RNA therapy for dyslipidemias.
Vupanorsen is in Phase 2 clinical development. It has completed one Phase 2 trial, and there are currently no active trials listed. The drug is investigational and has not been approved by the FDA for any indication.
Vupanorsen has been studied in one completed Phase 2 clinical trial, NCT04516291, titled A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70). This randomized, double-blind, placebo-controlled trial enrolled 286 participants with dyslipidemias, hyperlipidemias, and hyperlipoproteinemias across the United States, Canada, and Poland.